Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by prophetoffactzon Jan 12, 2023 1:28pm
85 Views
Post# 35218928

RE:RE:(AIM:MTPH.L)(Nasdaq:MTP) MTX-110 Ph1 Study Update

RE:RE:(AIM:MTPH.L)(Nasdaq:MTP) MTX-110 Ph1 Study Update"I assume the deal will be re-evaluted before Feb, 3rd,,we will be diluted back to 1% or less in that scenario!!"

The S&P Biotech ETF is now at a 4 month high on declining inflation fears giving some nice tone to the market in general. Midatech on the London Stock Exchange is up about 22% in the last five days. Midatech on NASDAQ is down ~27% in the last five days. It looks like there is aggressive dumping into the bid on Midatech on NASDAQ this week for whatever reason. The bid/ask spread can be quite large. 

If Midatch's stock price is below $.90 Midatech can walk away from the Armistice financing. The CEO, if I remember correctly, said he could have put together a syndicate as an option. It will be interesting to see what happens. The multi-product J&J option on xB3 expires a few days before BTI's shareholder vote. 
<< Previous
Bullboard Posts
Next >>